Fundraising Fox
Epics Therapeutics
Founded 2018 · 30 employees on LinkedIn · 2 known investors
Find your way into Epics Therapeutics
Sign up to see every warm intro you have to Epics Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Epics Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
EPICS Therapeutics develops RNA epigenetics-based cancer treatments, focusing on METTL3 inhibitors for cancers including non-small cell lung cancer, pancreatic cancer, ovarian cancer, and colorectal cancer where existing therapies are insufficient.
Investors · 2
Newton Biocapitallisted by Newton BiocapitalBrussels
How we know: Newton Biocapital's portfolio page · the VCSheet dataset · Not right? Tell us
Frequently asked questions
- What does Epics Therapeutics do?
- EPICS Therapeutics develops RNA epigenetics-based cancer treatments, focusing on METTL3 inhibitors for cancers including non-small cell lung cancer, pancreatic cancer, ovarian cancer, and colorectal cancer where existing therapies are insufficient.
- Who are Epics Therapeutics's investors?
- Epics Therapeutics's investors include Fund+, Newton Biocapital.